Zydus Lifesciences gets FDA final approval for Vigabatrin for Oral Solution
Zydus Lifesciences has bagged final approval for seizures drug Vigabatrin for Oral Solution USP, 500 mg from the US Food and Drug Administration (FDA). Vigabatrin for Oral Solution is a generic version of Sabril for Oral Solution. It is approved to treat refractory complex partial seizures as adjunctive therapy in patients aged two years and […]
